IVF
Conditions
Keywords
Myo-inositol, Melatonin, Co-enzyme q10, ovarian reserve
Brief summary
To evaluate the role of Myo-inositol, melatonin and co-enzyme Q10 on ovarian reserve parameters and ICSI outcome in poor ovarian responder
Detailed description
Each patient will be subjected to: Full history taking. Systematic clinical examination to assess the general condition, body mass index (BMI) and local pelvic physical findings and AFC by trans-vaginal ultrasound on day 2 to day 3 of menstruation. Routine labs as CBC, liver & kidney functions to exclude general disease as a contraindication for induction or pregnancy. Blood sample will be obtained for assessment of basal serum levels of FSH, LH, E2 on days 2- 3 of the cycle. PRL, AMH and TSH Ovarian Stimulation The patients will begin injections of recombinant FSH (rFSH, Gonal-F; Merck- Serono, Italy) from day 2-3 of menstruation, with daily dose of 300-450 IU adjusted according to individual conditions on the basis of the antral follicle count (AFC),hormonal profile, age, body mass index (BMI), and previous ovarian response, according to the standard operating procedures of the center. . For pituitary suppression, the patients will receive GnRH antagonist Cetrorelix (CETROTIDE 0.25Mg/d, Merck Serono, Germany) 0.25 mg/day subcutaneously from day 6 of induction until trigger day. The serum LH, estradiol levels as well as number and size of follicles will be monitored every two days, starting from stimulation day 6 until the day of hCG injection
Interventions
DRUGMyoinositol
an enzymatic isoform of inositol and belongs to the vitamin B complex family
DRUGCo-Enzyme Q10
a lipid-soluble quinone, acting as an effective antioxidant,
DRUGMelatonin
an indoleamine with low molecular weight that is synthesized by different cells and organs in the body. More importantly, melatonin is an outstanding antioxidant
DRUGFolic acid
control
Sponsors
Beni-Suef University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)
Eligibility
Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No
Inclusion criteria
* Infertile women who have one of the criteria of poor ovarian response as follows; * Antral follicle count less than 7 * Anti-Mullerian hormone level Less than 1.2 ng/ml
Exclusion criteria
1. Any endocrine or metabolic disorder such as hyperprolactinemia, diabetes and thyroid dysfunction 2. Any pelvic pathology such as hydrosalpinx, uterine anomaly. 3. Any male factor infertility such as Oligo-Astheno-Teratozoospermia (OAT) or azoospermia
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| pregnancy | 1 month of induction for ICSI trial | serum HCG positive |
Countries
Egypt
Contacts
Primary ContactSara S Sara Salem, MD
Outcome results
None listed